Back to School: How biopharma can reboot drug development. Access exclusive analysis here
On Monday, MEDX was up $1.01 (15%) to $7.84 on 10.5 million shares after it signed a 10-year deal with
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury